A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)

Go Back to All Clinical Trials

A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)

Brief description of study

if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial. The main goal of this phase I study is to evaluate the safety, tolerability, and efficacy of an investigational drug, oral KPT-9274 for the treatment of your diseases.

Clinical Study Identifier: s16-00464

ClinicalTrials.gov Identifier: NCT02702492

Principal Investigator: Daniel C Cho.

Other Investigators: Nina Beri, Arjun Vasant Balar, Vamsidhar Velcheti, Kathleen M Madden, Jeffrey S. Weber, Catherine M Diefenbach, Elaine Shum, Abraham Chachoua, Michael L. Grossbard, Bhavana Pothuri, Janice Mehnert, Jonathan B Kahn, Carol M Lee, Yelena Novik, Benjamin James Raudabaugh, Daniel J Becker, Sylvia Adams, Theresa Ryan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies